Abstract
Variant liver oestrogen receptor transcripts in hepatocellular carcinoma are associated with aggressive clinical course and unresponsiveness to tamoxifen. To evaluate the impact on survival and on tumour growth of megestrol (progestin drug acting at post-receptorial level) we enrolled 45 patients with HCC characterized by variant liver oestrogen receptors in a prospective, randomized study with megestrol vs. placebo. Presence of variant oestrogen receptors was determined by RT/PCR. 24 patients were randomized to no treatment and 21 to therapy with megestrol 160 mg day–1. Results were analysed by Kaplan-Meier and Cox methods. Survival of hepatocellular carcinoma characterized by variant oestrogen receptors was extremely poor (median survival 7 months); megestrol significantly improved survival (18 months) (P = 0.0090). Tumour growth at one year was significantly slowed down in megestrol-treated patients (P = 0.0212). Bilirubin levels, presence of portal thrombosis, HBV aetiology and treatment were identified at univariate analysis as factors significantly associated with survival; at multivariate analysis, only megestrol therapy (P = 0.0003), presence of HBV infection (P = 0.0009) and presence of portal vein thrombosis (P = 0.0051) were factors independently related with survival. (1) Megestrol slows down the aggressive tumour growth of patients with hepatocellular carcinoma characterized by variant estrogen receptors and (2) is also able to favourably influence the course of disease, more than doubling median survival. © 2001 Cancer Research Campaign
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Castells A, Bruix J, Bru C, Fuster J, Vilana R, Navasa M, Ayuso C, Boix L, Visa J and Rodes J (1993) Treatment of small hepatocellular carcinoma in cirrhotic patients: a cohort study comparing surgical resection and percutaneous ethanol injection. Hepatology 18: 1121–1126
Castells A, Bruix J, Bru C, Ayuso C, Roca M, Boix L, Vilana R and Rodes J (1995) Treatment of hepatocellular carcinoma with tamoxifen: a double-blind trial in 120 patients. Gastroenterology 109: 917–922
Chao Y, Chan W-K, Wang S-S, Lai KH, Chi CW, Lin CY, Chan A, Whang PENG-J, Lui WY and Lee SD (1991) Phase II study of megestrol acetate in the treatment of hepatocellular carcinoma. J Hepatol Gastroenterol 12: 277–281
Cox DR (1972) Regression models and life tables (with discussion). J R Stat Soc B 34: 187–220
Elba S, Giannuzzi V, Misciagna G and Manghisi OG (1994) Randomized controlled trial of tamoxifen versus placebo in inoperable hepatocellular carcinoma. It J Gastroenterol 26: 66–68
Engstrom PF, Levin B, Moertel CG and Schutt A (1990) A Phase II trial in hepatocellular carcinoma. Cancer 65: 2641–2643
Farinati F, Salvagnini M, De Maria N, Fornasiero A, Chiaramonte M, Rossaro L and Naccarato R (1990) Unresectable hepatocellular carcinoma. A prospective controlled trial with tamoxifen. J Hepatol 11: 297–301
Fuqua SAW, Fitzgerald SD, Chamness GC, Tandon AK, McDonnell DP, Nawaz Z, O’Malley BW and McGuire WL (1991) Variant human breast tumor estrogen receptor with constitutive transcriptional activity. Cancer Res 51: 105–109
Gallo C CLIP study group (1998) Tamoxifen in the treatment of hepatocellular carcinoma: a randomised controlled trial. Lancet 352: 17–20
Kaplan EL and Meier P (1958) Non-parametric estimation for incomplete observation. Am Stat Assoc 53: 457–481
Martinez-Cerezo FJ, Tomas A, Donoso L, Enriquez-J Guarner C, Balanzo J, Martinez-Nogueras A and Vilardell F (1994) Controlled trial of tamoxifen in patients with advanced hepatocellular carcinoma. J Hepat 20: 702–706
Mazzaferro V, Regalia E, Doci R, Andreola S; Pulvirenti A, Bozzetti F, Montalto F, Ammatuna M, Morabito A and Gennari L (1996) Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 334: 693–699
Simonetti RG, Liberati A, Angiolini C and Pagliaro L (1997) Treatment of hepatocellular carcinoma: a systematic review of randomized controlled trials. Ann Oncol 8: 117–136
Vilana R, Bruix J, Bru C, Ayuso C, Sole M and Rodes J (1992) Tumor size determines the efficacy of percutaneous ethanol injection for treatment of small hepatocellular carcinoma. Hepatology 16: 353–357
Villa E, Baldini G, Pasquinelli C, Melegari M, Cariani E, Di-Chirico G and Manenti F (1988) Risk factors for hepatocellular carcinoma in Italy: HBV virus, alcohol, male sex. Cancer 62: 611–615
Villa E, Camellini L, Dugani A, Zucchi F, Grottola A, Merighi A, Buttafoco P, Losi L and Manenti F (1995) Variant estrogen receptor messenger RNA species detected in human primary hepatocellular carcinoma. Cancer Res 55: 498–500
Villa E, Camellini L, Dugani A, Buttafoco P, Grottola A and Manenti F (1996a) Variant liver estrogen receptors and response to tamoxifen. Gastroenterology (Letter) 111: 271–272
Villa E, Dugani A, Fantoni E, Camellini L, Buttafoco P, Grottola A, Pompei G, De-Santis M, Ferrari A and Manenti F (1996b) Type of estrogen receptor determines response to antiestrogen therapy in hepatocellular carcinoma. Cancer Res 56: 3883–3885
Villa E, Fantoni E, Moles A, Camellini L, Buttafoco P, Grottola A, Ferretti I, Scarcelli A and Manenti F (1997) Survival of patients with hepatocellular carcinoma is determined by type of liver estrogen receptors. Hepatology 26: 247A
Villa E, Dugani A, Moles A, Camellini L, Grottola A, Buttafoco P, Merighi A, Ferretti I, Esposito P, Miglioli L, Bagni A, Troisi R, De-Hemptinne B, Praet M, Callea F and Manenti F (1998) Variant liver estrogen receptor transcripts already occur at an early stage of chronic liver disease. Hepatology 27: 983–988
Zaman SN, Melia WM, Johnson RD, Portmann BC, Johnson PJ and Williams R (1985) Risk factors in development of hepatocellular carcinoma in cirrhosis: prospective study of 613 patients. Lancet 1: 1357–1360
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Villa, E., Ferretti, I., Grottola, A. et al. Hormonal therapy with megestrol in inoperable hepatocellular carcinoma characterized by variant oestrogen receptors. Br J Cancer 84, 881–885 (2001). https://doi.org/10.1054/bjoc.2000.1534
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2000.1534
Keywords
This article is cited by
-
Efficacy and Safety Results from a Phase 2, Randomized, Double-Blind Study of Enzalutamide Versus Placebo in Advanced Hepatocellular Carcinoma
Clinical Drug Investigation (2021)
-
“Sarcopenia and intramuscular fat deposition are associated with poor survival in Indonesian patients with hepatocellular carcinoma: a retrospective study”
BMC Gastroenterology (2019)
-
Males develop faster and more severe hepatocellular carcinoma than females in krasV12 transgenic zebrafish
Scientific Reports (2017)
-
Role of estrogen in hepatocellular carcinoma: is inflammation the key?
Journal of Translational Medicine (2014)
-
Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: a representative population prospective cohort study of 800,000 individuals
BMC Cancer (2011)